ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0210 • ACR Convergence 2023

    Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors

    Hilde Ørbo1, Asia-Sophia Wolf2, Kristin Hammersbøen Bjørlykke3, Sarah E. Josefsson2, Guri Solum2, Ingrid Fadum Kjønstad4, Ingrid Jyssum1, Ingrid Christensen1, Anne Therese Tveter1, Joseph Sexton1, Grete B. Kro5, Gunnveig Grødeland6, Tore Kvien1, Jørgen Jahnsen3, John Torgils Vaage7, Espen Haavardsholm1, Sella Provan8, Hassen Kared9, Ludvig A. Munthe7, Kristin Kaasen Jørgensen3, Silje Watterdal Syversen1, Siri Mjaaland2 and Guro Goll1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Norwegian Institute of Public Health, Oslo, Norway, 3Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 4National Institute of Public Health, Oslo, Norway, 5Department of Microbiology, Oslo University Hospital, Oslo, Norway, 6Department of Immunology, Oslo University Hospital, Oslo, Norway, 7Department of Immunology, Oslo University Hospital, Oslo, Norway, 8Diakonhjemmet Hospital, Oslo, Norway, 9Department of Immunology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…
  • Abstract Number: 0932 • ACR Convergence 2023

    The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing

    Lingzhen Hu1, Jianxin Tu1, Jiajun Gui2, Mengyuan Fang2, Xiaowei Chen1 and Li Sun1, 1The First Affliated Hospital of Wenzhou Medical University, Wenzhou, China, 2The First Clinical College, Wenzhou Medical University, Wenzhou, China

    Background/Purpose: This study aimed to analyze the immune cell profiles, especially B cells and B-cell receptor (BCR) of systematic lupus erythematosus (SLE) patients with or…
  • Abstract Number: 1553 • ACR Convergence 2023

    Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

    Yeliz Yagiz Ozogul1, Sinem Nihal Esatoglu2, Murat Ozogul3, Osman Kizilkilic4, Yesim Ozguler5, Ugur Uygunoglu6, Vedat Hamuryudan2 and Gulen Hatemi2, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey

    Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
  • Abstract Number: 2116 • ACR Convergence 2023

    Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study

    Hyungjin Kim1, Yeonghee Eun2, Seonyoung Kang3, Jaejoon Lee3, Hoon-Suk Cha3, Jong Ho Cho4, Kwangmo Yang4, Kyungdo Han5 and Dong Wook Shin6, 1Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, 6Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…
  • Abstract Number: 2566 • ACR Convergence 2023

    Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database

    Léa Bastard1, pascal claudepierre2, Laetitia Penso3, Emilie Sbidian4 and Laura PINA VEGAS5, 1Henri Mondor University Hospital (APHP) / Rheumatology Department, Créteil, France, 2Universitary Henri Mondor Hospital, Creteil, France, 3Université Paris Est Créteil, Créteil, France, 4Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, 5Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France

    Background/Purpose: Targeted therapies have demonstrated their efficacy in the treatment of psoriatic arthritis (PsA), with an increased risk of serious infections. However, a comparison of…
  • Abstract Number: 0211 • ACR Convergence 2023

    COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study

    Hilde Ørbo1, Ingrid Jyssum1, Joseph Sexton1, Anne Therese Tveter1, Ingrid Christensen1, Kristin Hammersbøen Bjørlykke2, Grete B. Kro3, Tore Kvien1, Ludvig A. Munthe4, Gunnveig Grødeland5, Siri Mjaaland6, Espen Haavardsholm1, John Torgils Vaage4, Kristin Kaasen Jørgensen2, Sella Provan7, Silje Watterdal Syversen1 and Guro Goll1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 3Department of Microbiology, Oslo University Hospital, Oslo, Norway, 4Department of Immunology, Oslo University Hospital, Oslo, Norway, 5Department of Immunology, Oslo University Hospital, Oslo, Norway, 6Norwegian Institute of Public Health, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated vaccine responses and are prone to severe infections. Knowledge of COVID-19 outcome following…
  • Abstract Number: 0970 • ACR Convergence 2023

    Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change

    Diane Lacaille1, J. Antonio Avina-Zubieta2, Yufei Zheng2, Na Lu2 and Hui Xie3, 1Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Simon Fraser University, Richmond, BC, Canada

    Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…
  • Abstract Number: 1584 • ACR Convergence 2023

    Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

    Arielle Mendel1, Hassan Behlouli2, Evelyne Vinet1, Jeffrey Curtis3 and Sasha Bernatsky2, 1McGill University Health Centre, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
  • Abstract Number: 2120 • ACR Convergence 2023

    Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections

    Misaki Yoshida1, takeshi Zoshima2, Ichiro Mizushima2 and Mitsuhiro Kawano2, 1Kanazawa University, Fukui, Japan, 2Kanazawa University, Kanazawa, Japan

    Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…
  • Abstract Number: 0215 • ACR Convergence 2023

    Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort

    Erika Biegelmeyer1, Mariana Freitas de Aguiar1, Priscila Dias Cardoso Ribeiro1, Ketty Lysie Libardi Lira Machado2, Maria da Penha Gomes Gouveia2, Camila Maria Paiva França Telles3, Samuel Elias Basualto Dias3, Natália Sarzi Sartori4, Thaís Evelyn Karnopp5, Vanessa de Oliveira Magalhães1, Flávia Maria Matos Melo Campos Peixoto1, Laiza Hombre Dias2, Débora Marques Veghini2, Rodrigo Vieira de Rezende6, Katia Lino Baptista6, Ana Karla Guedes de Melo7, Vitor Alves Cruz8, Maria Cecília Dias Corrêa9, Adriana Maria Kakehasi10, Rejane Maria Rodrigues de Abreu Vieira11, Valderilio Feijó Azevedo12, Olindo Assis Martins-Filho13, Charlles Heldan de Moura Castro1, Ricardo Xavier14, Andréa Teixeira-Carvalho13, Viviane Angelina de Souza9, Odirlei André Monticelo15, Marcelo Pinheiro16, Edgard Torres dos Reis Neto1, Emilia Sato1, Gilda Ferreira17, Gecilmara Pileggi18, Valeria Valim19 and Alexandre wagner Silva de Souza20, 1Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 2Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, 3Universidade Federal do Amazonas, Manaus, Brazil, 4Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 6Universidade Federal Fluminense, Niterói, Brazil, 7Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, 8Universidade Federal de Goiás, Goiânia, Brazil, 9Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, 10Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 11Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, 12Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, 13Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, 14Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 15Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 16UNIFESP/ EPM, São Paulo, Brazil, 17Federal University of Minas Gerais, Belo Horizonte, Brazil, 18UNIFESP, Ribeirão Preto, Brazil, 19Universidade Federal do Espírito Santo, Vitória, Brazil, 20Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
  • Abstract Number: 0981 • ACR Convergence 2023

    Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors

    Aron Hjalti Bjornsson1, Telma Thrastardottir2, Bjorn Gudbjornsson3 and Thorvardur Love4, 1Landspitali University Hospital and the University of Iceland, Reykjavík, Iceland, 2University of Iceland, Reykjavik, Iceland, 3Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 4Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland

    Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
  • Abstract Number: 1619 • ACR Convergence 2023

    Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis

    Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC

    Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
  • Abstract Number: 2267 • ACR Convergence 2023

    Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus

    Hsin-Hua Chen1 and Wen-Nan Huang2, 1Taichung Veterans General Hospital, Taichung, Taiwan, 2Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Veterans General Hospital, College of Medicine National Chung Hsing University, Department of Business Administration, Ling-Tung University, Taichung, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…
  • Abstract Number: 0218 • ACR Convergence 2023

    Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases

    Yumeko Kawano1, Xiaosong Wang1, Naomi Patel2, Grace Qian1, Emily Kowalski1, Katarina Bade3, Kathleen Vanni1, Accelerating Medicines Partnership (AMP): RA/SLE1, Zachary Williams2, Claire Cook2, Shruthi Srivatsan2, Zachary Wallace4 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
  • Abstract Number: 0983 • ACR Convergence 2023

    Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study

    I-Feng Lin1, Hsin-Hua Chen2, Theodore Tsai3 and Nicole Huang4, 1National Yang Ming Chiao Tung University, Taipei, Taiwan, 2Taichung Veterans General Hospital, Taichung, Taiwan, 3Takeda Vaccines, Cambridge, MA, 4Master of Public Health Program, National Yang Ming Chiao Tung University, Taipei, Taiwan

    Background/Purpose: Dengue is the leading vectorborne disease globally with half of the global population at risk, including Puerto Rico in the United States. Previously, we…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology